GLP-1 receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
定量分析的主流方法是反相高效液相色谱联用紫外或质谱检测，利用肽在疏水固定相上的保留行为确定纯度与含量。对于生物基质中的浓度测定，常采用液相色谱串联质谱，并配合固相萃取或蛋白沉淀进行样品前处理。免疫分析法也可使用，但可能受到结构相关肽的交叉反应干扰。
纯度评估通常综合反相色谱、体积排阻色谱与质谱三方面信息：前者反映疏水性杂质，后者反映聚集体，质谱则确认分子量与主要降解产物。有关降解途径的完整图谱——例如脱酰胺、氧化与水解各占多大比例——在不同储存条件下仍有差异，属于需要逐案验证的问题。
=== Etymology === The genus name Moringa derives from the Tamil word, murungai, meaning "twisted pod", alluding to the young fruit. The specific name oleifera is derived from the Latin words oleum "oil" and ferre "to bear". The plant has numerous common names across regions where it is cultivated, with drumstick tree, horseradish tree, or simply moringa used in English.
==== Periplanone B ==== In 1979, Still reported the first total synthesis of periplanone B, the potent sex pheromone of the American cockroach. Although the structural connectivity of this compound had been established spectroscopically, Still's synthesis confirmed the relative stereochemical relationships present in this natural product. A key step in this synthesis makes use of an anionic oxy-Cope rearrangement to form the macrocyclic 10-membered ring found in periplanone B. In this transformation, the initial tertiary alcohol was treated with potassium hydride and 18-crown-6 at elevated temperature to induce the rearrangement, and the resulting enolate was trapped with chlorotrimethylsilane to form the macrocyclic silyl enol ether as a single diastereomer. This intermediate was then transformed into a key enone substrate over the course of five steps including Rubottom oxidation, TBS protection of the secondary alcohol, and formation of the exocyclic alkene via a selenoxide rearrangements.
Consultant Urologist, South Tyneside and Sunderland NHS Foundation Trust. For services to the NHS. Dr. Benjamin Marc Ellis. For services to Healthcare, to Equality and to the Jewish Community. Audley Horace English. Co-Founder, Society of Black Architects. For services to Architecture and Sustainability. Professor Stephen James Weston Evans. Emeritus Professor of Pharmacoepidemiology, London School of Hygiene and Tropical Medicine. For services to the Safety of Medicines. Stephen Wynne Evans. Founder, Belief. For voluntary and charitable services in North Wales. Helen Adesuwa Imatitkua Fadipe. Founder and Chair, BAME Planners Network. For services to Town Planning. Paul Fairweather. Trustee, Breakthrough Ltd. For services to Disabled People and to the LGBT Community in the North West. Catherine Susan, Baroness Fall. Lately Non Executive Director, Cultural Recovery Board. For services to Culture. Rhiane Estelle Fatinikun. Founder, Black Girls Hike. For services to Nature and to Diversity. Julie Patricia Felix. For services to Dance Education. James St John Fenny. Head of Office, Public Defender Service and Transplant Surgery Ambassador. For services to Criminal Justice and to Organ Donor Awareness. Dr. Julia Helen Fentem. Executive Vice President, Safety, Environmental and Regulatory Science, Unilever. For services to Human Health and Animal Welfare. Jacqueline Ferguson. President, London College of Dance Network and Volunteer, Healthwatch (Kensington and Chelsea). For services to the community in London. Lucy Catherine Ferguson. Founder and Director, Mediorite.
Sources: en.wikipedia.org
The Unitized Group Ration – M (UGR-M), formerly the Unitized Group Ration – B (UGR-B), is the successor to the B-ration, and consists of packaged and dehydrated unprepared food intended to be assembled and prepared in a field kitchen. Designed to suit the needs of the U.S. Marine Corps, each UGR-M comes with ingredients that are primarily tailored toward specific recipes but could potentially be used to prepare other dishes. The UGR-M has 7 breakfast menus and 14 lunch/dinner menus. Each meal provides an average of 1,300 kcal. Each UGR-M module contains 50 meals, with each pallet holding 400 meals. UGR-M modules have a minimum shelf life of 18 months at 80 °F (26.6 °C).
One method of feeding libraries into the microfluidic device uses single cell encapsulation, in which droplets contain a maximum of one cell each. This avoids confounding results that could be generated by having multiple cells, and consequently multiple genotypes, in a single droplet, while maximizing the efficiency of resource consumption. This method enables the detection of secreted proteins and proteins on the cell membrane. The addition of a cell lysate to the droplets, which breaks down the cellular membrane such that the intracellular species are freely available within the droplet, expands the capabilities of the single cell encapsulation method to analyze intracellular proteins. The library can also be made entirely in vitro (i.e., not in its biological/cellular context) such that the content of the droplet is exclusively a mutated DNA strand. The in vitro system requires PCR and the use of in vitro transcription and translation (IVTT) systems to generate the desired protein in the droplet for analysis. Sorting of droplets for directed evolution is primarily done by fluorescence detection (e.g., fluorescence-activated droplet sorting (FADS)), however recent developments in a absorbance-based sorting methods, known as absorbance-activated droplet sorting (AADS), have expanded the diversity of substrates that can undergo directed evolution through a droplet-based microfluidic device. Recently, sorting capability has even expanded to the detection of NADPH levels and has been used to create higher activity NADP-dependent oxidoreductases.
If this is the case, such a duplication must have happened early in animal evolution (more than 700 million years ago), as genes that encode for all three subunits of troponin have been found in every invertebrate phyla except the Cnidaria (or equivalently, all Bilaterian phyla). The ancestral gene pair most closely resembled TNNI2-TNNT3.
The political aim was to discredit the Japanese-sponsored republic and build the concept of a functioning democracy as a grass roots level, while the economic objective was to prevent the enemy's looting. The result was the creation of the Central Luzon Bureau (CLB), an organization meant to lead resistance against the Japanese. Key positions were filled out as follows:
Sources: en.wikipedia.org
On the other hand, if the idea of a smaller Germany won out, the German crown could of course not possibly go to the Emperor of Austria, but would naturally be offered to the head of the largest and most powerful German state outside of Austria—the King of Prussia. The contest between the two ideas, quickly developed into a contest between Austria and Prussia. After Prussia decisively won the Seven Weeks War, this question was solved; Austria lost no territories to Prussia as long as they remained out of German affairs.
== Gene == Common aliases of EPCIP are C21orf62, C21orf120, PRED81, and B37. EPCIP is located on chromosome 21 in humans, and is specifically at the q22.11 position. The EPCIP gene is 4132 base pairs in length and contains five exons.
== Trends == In recent years, a new type of benzodiazepine known as 'Designer benzodiazepines' are becoming available in Europe. It is based on the premise of modifying the structure of illicit drugs to evade international control measures. By early 2021, EMCDDA has monitored 30 designer benzodiazepines through the EWS. However, not much information is available regarding the market size of new benzodiazepines. Seizures reports from police and customs authorities have shown that new benzodiazepine is not of great interest compared to other NPS groups. In 2019, 4% of police seizures is attributed to benzodiazepines.
=== Intravenous === Vancomycin must be given intravenously for systemic therapy since it is poorly absorbed from the intestine. Vancomycin is a large hydrophilic molecule that partitions poorly across the gastrointestinal mucosa. Due to its short half-life, it is often injected twice daily.
== History == UK-5099 (JXL001), the earlier MPC inhibitor from which suvomipic was derived, was first described in the scientific literature by 1975. Suvomipic is under development by Pelage Pharmaceuticals. In 2025, it was reported that lab work on the drug had been ongoing for almost a decade. It originated at the University of California, Los Angeles (UCLA), with Pelage Pharmaceuticals being founded and spun out of UCLA in 2018 by three scientists at the university. These academics included Bill Lowry, Heather Christofk, and Michael Jung. The chief medical officer (CMO) of the company is Qing Yu Christina Weng. Pelage Pharmaceuticals was named after the French word for "coat of fur" and "PP405" was named after the company and the 405 freeway that goes through Los Angeles. The first human clinical trials of suvomipic started in 2023 in Orange County.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.